JP2025501630A - 化合物 - Google Patents
化合物 Download PDFInfo
- Publication number
- JP2025501630A JP2025501630A JP2024538682A JP2024538682A JP2025501630A JP 2025501630 A JP2025501630 A JP 2025501630A JP 2024538682 A JP2024538682 A JP 2024538682A JP 2024538682 A JP2024538682 A JP 2024538682A JP 2025501630 A JP2025501630 A JP 2025501630A
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- cycloalkyl
- alkyl
- heterocycloalkyl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021904274 | 2021-12-24 | ||
| AU2021904274A AU2021904274A0 (en) | 2021-12-24 | Compounds | |
| PCT/AU2022/051593 WO2023115167A1 (en) | 2021-12-24 | 2022-12-23 | Compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501630A true JP2025501630A (ja) | 2025-01-22 |
| JP2025501630A5 JP2025501630A5 (enExample) | 2026-01-07 |
Family
ID=86900852
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538682A Pending JP2025501630A (ja) | 2021-12-24 | 2022-12-23 | 化合物 |
| JP2024538674A Pending JP2025501629A (ja) | 2021-12-24 | 2022-12-23 | 化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538674A Pending JP2025501629A (ja) | 2021-12-24 | 2022-12-23 | 化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20250074873A1 (enExample) |
| EP (2) | EP4452937A4 (enExample) |
| JP (2) | JP2025501630A (enExample) |
| CN (2) | CN118715204A (enExample) |
| CA (2) | CA3244229A1 (enExample) |
| WO (2) | WO2023115167A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| KR102946120B1 (ko) | 2019-02-27 | 2026-03-30 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클 |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| WO2022221415A2 (en) | 2021-04-13 | 2022-10-20 | The Regents Of The University Of California | Tetracyclic compounds for treating brain disorders |
| EP4396162A4 (en) | 2021-09-03 | 2025-11-12 | Alexander Shulgin Res Institute Inc | ASYMMETRIC ALLYL TRYPTAMINES |
| JP2025502615A (ja) | 2021-12-15 | 2025-01-28 | デリックス セラピューティクス,インク. | フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用 |
| CA3238440A1 (en) | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| CA3253725A1 (en) * | 2022-05-20 | 2023-11-23 | Caamtech, Inc. | TRYPTAMINE DERIVATIVES |
| AU2023323907A1 (en) * | 2022-08-11 | 2025-02-20 | Gilgamesh Pharmaceuticals, Inc. | Tryptamines and methods of treating mood disorders |
| CA3265884A1 (en) * | 2022-08-31 | 2024-03-07 | Cybin Irl Limited | TRYPTAMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE |
| CN121866243A (zh) * | 2023-09-07 | 2026-04-14 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 致幻化合物、其制备方法及其用途 |
| WO2025137581A1 (en) * | 2023-12-21 | 2025-06-26 | Atai Therapeutics, Inc. | Novel tetrahydro pyridine substituted indole and azaindoles, compositions of matter and pharmaceutical compositions |
| US12679847B1 (en) | 2025-08-04 | 2026-07-14 | Nalu Bio, Inc. | Aryl-substituted n-alkyl indoles and their use as pharmacologically active agents |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1928892A (en) * | 1991-06-21 | 1993-01-25 | Smithkline Beecham Plc | Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists |
| GB9718833D0 (en) * | 1997-09-04 | 1997-11-12 | Merck Sharp & Dohme | Therapeutic agents |
| AU767009B2 (en) * | 1998-12-11 | 2003-10-30 | Virginia Commonwealth University | Selective 5-HT6 receptor ligands |
| SI1379239T1 (sl) * | 2001-03-29 | 2008-02-29 | Lilly Co Eli | N-(2-ariletil)benzilamini, uporabljeni kot antagonisti receptorja 5-ht6 |
| KR20050010512A (ko) * | 2002-06-12 | 2005-01-27 | 스미또모 세이야꾸 가부시키가이샤 | 인돌, 인다졸 및 벤즈아졸류 |
| CA2508290C (en) * | 2002-12-20 | 2017-02-28 | Ciba Specialty Chemicals Holding Inc. | Synthesis of amines and intermediates for the synthesis thereof |
| ES2564804T3 (es) * | 2004-02-12 | 2016-03-29 | Mitsubishi Tanabe Pharma Corporation | Compuesto de indazol y uso farmacéutico del mismo |
| WO2006047032A2 (en) * | 2004-09-27 | 2006-05-04 | Organix, Inc. | Indole compounds useful as serotonin selective agents |
| WO2007046112A1 (en) * | 2005-10-19 | 2007-04-26 | Suven Life Sciences Inc. | Arylthioether tryptamine derivatives as functional 5-ht6 ligands |
| WO2008046155A1 (en) * | 2006-10-20 | 2008-04-24 | Dia-B Tech Limited | Methods for regulating glucose homeostasis and agents therefor |
| US20090318527A1 (en) * | 2008-02-11 | 2009-12-24 | Howard Sard | Indole compounds and methods of use thereof |
| BRPI0916395A2 (pt) * | 2008-07-30 | 2016-02-16 | Ferrer Int | compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno |
| US8349898B2 (en) * | 2008-11-18 | 2013-01-08 | Wisconsin Alumni Research Foundation | Sigma-1 receptor ligands and methods of use |
| US8912220B2 (en) * | 2009-08-10 | 2014-12-16 | Galenea Pharmaceuticals | Compounds and methods of use thereof |
| CN103601683B (zh) * | 2010-04-16 | 2016-03-30 | 中国科学院上海药物研究所 | 苯并杂环类化合物及其制备方法和用途 |
| USRE47009E1 (en) * | 2011-02-01 | 2018-08-28 | The Children's Hospital Of Philadelphia | HDAC inhibitors and therapeutic methods using the same |
| LT4084791T (lt) * | 2020-02-18 | 2025-02-25 | Gilgamesh Pharmaceuticals, Inc. | Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti |
| WO2021179091A1 (en) * | 2020-03-12 | 2021-09-16 | Bright Minds Biosciences Inc. | 3-(2-(aminoethyl)-indol-4-ol derivatives, methods of preparation thereof, and the use as 5-ht2 receptor modulators |
| IL312785B2 (en) * | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| US20230014907A1 (en) * | 2020-06-12 | 2023-01-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| WO2022246554A1 (en) * | 2021-05-26 | 2022-12-01 | Bright Minds Biosciences Inc. | Heterocyclic compounds and methods of preparation thereof |
-
2022
- 2022-12-23 CA CA3244229A patent/CA3244229A1/en active Pending
- 2022-12-23 US US18/723,836 patent/US20250074873A1/en active Pending
- 2022-12-23 EP EP22908928.9A patent/EP4452937A4/en active Pending
- 2022-12-23 JP JP2024538682A patent/JP2025501630A/ja active Pending
- 2022-12-23 CN CN202280091813.9A patent/CN118715204A/zh active Pending
- 2022-12-23 US US18/723,719 patent/US20250101038A1/en active Pending
- 2022-12-23 EP EP22908929.7A patent/EP4452938A4/en active Pending
- 2022-12-23 CN CN202280091811.XA patent/CN118696029A/zh active Pending
- 2022-12-23 WO PCT/AU2022/051593 patent/WO2023115167A1/en not_active Ceased
- 2022-12-23 WO PCT/AU2022/051592 patent/WO2023115166A1/en not_active Ceased
- 2022-12-23 JP JP2024538674A patent/JP2025501629A/ja active Pending
- 2022-12-23 CA CA3244224A patent/CA3244224A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118715204A (zh) | 2024-09-27 |
| EP4452937A4 (en) | 2025-12-03 |
| WO2023115167A1 (en) | 2023-06-29 |
| WO2023115166A1 (en) | 2023-06-29 |
| US20250074873A1 (en) | 2025-03-06 |
| EP4452938A4 (en) | 2025-12-03 |
| CN118696029A (zh) | 2024-09-24 |
| JP2025501629A (ja) | 2025-01-22 |
| CA3244229A1 (en) | 2023-06-29 |
| US20250101038A1 (en) | 2025-03-27 |
| CA3244224A1 (en) | 2023-06-29 |
| EP4452937A1 (en) | 2024-10-30 |
| EP4452938A1 (en) | 2024-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250163044A1 (en) | Compounds | |
| US20250101038A1 (en) | Compounds | |
| US12415804B2 (en) | Compounds for activating a serotonin receptor | |
| CN117337289A (zh) | 用于治疗脑病症的四环化合物 | |
| US20250333371A1 (en) | Compounds | |
| WO2025104490A1 (en) | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto | |
| US12428380B2 (en) | Compounds | |
| WO2025118034A1 (en) | Compounds active at the serotonergic 5-ht2a receptor | |
| WO2025104491A1 (en) | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251223 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251223 |